Combination drug therapy for dyslipidemia.

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Dyslipidemia significantly impacts cardiovascular prognosis, with elevated low-density lipoprotein (LDL) cholesterol and triglycerides being key contributors to atherosclerosis.
• Current treatment guidelines recommend target LDL cholesterol levels below 100 mg/dL, yet many patients do not achieve these goals.
• Triglyceride levels are increasingly recognized as critical mediators of atherosclerotic progression and cardiovascular events.

Purpose of the Study:

• To review the importance of achieving target lipid levels for cardiovascular risk reduction.
• To discuss combination therapy strategies for managing mixed dyslipidemia.
• To highlight the role of statins, niacin, and omega-3 supplementation in achieving lipid goals.

Main Methods:

• Literature review of studies on dyslipidemia treatment and cardiovascular event rates.
• Analysis of treatment targets for LDL cholesterol and triglycerides.
• Evaluation of combination pharmacotherapy and adjunctive agents.

Main Results:

• Statin therapy reduces cardiovascular events but often fails to achieve target LDL cholesterol levels (<100 mg/dL).
• Target triglyceride levels should also be considered (<100 mg/dL).
• Combination therapy, particularly statin with niacin, is frequently required. Omega-3 supplementation is beneficial for elevated triglycerides.

Conclusions:

• Achieving target LDL cholesterol and triglyceride levels is essential for effective dyslipidemia management and improved cardiovascular outcomes.
• Combination therapy, including statins with niacin and omega-3s, is often necessary to meet lipid goals.
• Emerging agents like second-generation bile acid sequestrants offer additional LDL reduction.